Mayukh Sukhatme - 29 Dec 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
President & CIO, Director
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme
Issuer symbol
ROIV
Transactions as of
29 Dec 2025
Net transactions value
-$28,902,513
Form type
4
Filing time
31 Dec 2025, 21:00:51 UTC
Previous filing
19 Dec 2025
Next filing
11 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sukhatme Mayukh President & CIO, Director C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme 31 Dec 2025 0001750050

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Options Exercise $9,489,179 +748,358 +4% $12.68 19,584,905 29 Dec 2025 Direct
transaction ROIV Common Shares Sale $6,780,119 -311,873 -1.6% $21.74 19,273,032 29 Dec 2025 Direct F1, F2
transaction ROIV Common Shares Other $9,489,184 -436,485 -2.3% $21.74 18,836,547 29 Dec 2025 Direct F1, F4
transaction ROIV Common Shares Options Exercise $31,064,440 +2,449,877 +13% $12.68 21,286,424 31 Dec 2025 Direct
transaction ROIV Common Shares Sale $22,122,381 -1,018,995 -4.8% $21.71 20,267,429 31 Dec 2025 Direct F1, F3
transaction ROIV Common Shares Other $31,064,448 -1,430,882 -7.1% $21.71 18,836,547 31 Dec 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -748,358 -57% $0.000000 555,840 29 Dec 2025 Common Shares 748,358 $12.68 Direct F5
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -2,449,877 -96% $0.000000 95,718 31 Dec 2025 Common Shares 2,449,877 $12.68 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F2 These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.90, inclusive.
F3 These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.74, inclusive.
F4 Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
F5 Award of stock options to purchase Common Shares that is fully vested.